Literature DB >> 7692369

Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts.

K Pajusola1, O Aprelikova, E Armstrong, S Morris, K Alitalo.   

Abstract

FLT4 is a recently cloned gene encoding a transmembrane tyrosine kinase related to the FLT1 and KDR/FLK1 vascular endothelial growth factor receptors. We have previously shown that FLT4 is expressed as transcripts of 4.5 and 5.8 kb in several human fetal and adult tissues. Here we show that these transcripts encode two polypeptides, FLT4s (short) and FLT41 (long), which are proteolytically processed in transfected cells and leukemia cells and which have different carboxy terminal tails. The 3' coding region of the 5.8 kb mRNA was found to be 65 codons longer than that of the the 4.5 kb mRNA. Analysis of the genomic structure of the region encoding the two carboxy termini revealed that the two transcripts are generated by alternative polyadenylation and subsequent alternative splicing during RNA processing. Our findings thus show regulation of FLT4 structure in the carboxy terminal tail considered important for receptor function. The significance of the two forms may relate to the role of additional potential autophosphorylation sites in the FLT4 long form.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692369

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

1.  Proteolytic processing regulates receptor specificity and activity of VEGF-C.

Authors:  V Joukov; T Sorsa; V Kumar; M Jeltsch; L Claesson-Welsh; Y Cao; O Saksela; N Kalkkinen; K Alitalo
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

Review 2.  Alternative poly(A) site selection in complex transcription units: means to an end?

Authors:  G Edwalds-Gilbert; K L Veraldi; C Milcarek
Journal:  Nucleic Acids Res       Date:  1997-07-01       Impact factor: 16.971

3.  Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing.

Authors:  K Paavonen; P Puolakkainen; L Jussila; T Jahkola; K Alitalo
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

4.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).

Authors:  M G Achen; M Jeltsch; E Kukk; T Mäkinen; A Vitali; A F Wilks; K Alitalo; S A Stacker
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

5.  Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4.

Authors:  J Lee; A Gray; J Yuan; S M Luoh; H Avraham; W I Wood
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

6.  Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome.

Authors:  Yan Zhou; Michael McMaster; Kirstin Woo; Mary Janatpour; Jean Perry; Terhi Karpanen; Kari Alitalo; Caroline Damsky; Susan J Fisher
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

7.  Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis.

Authors:  S J Mandriota; L Jussila; M Jeltsch; A Compagni; D Baetens; R Prevo; S Banerji; J Huarte; R Montesano; D G Jackson; L Orci; K Alitalo; G Christofori; M S Pepper
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

8.  Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.

Authors:  Hanna Sallinen; Maarit Anttila; Johanna Narvainen; Jonna Koponen; Kirsi Hamalainen; Ivana Kholova; Tommi Heikura; Pyry Toivanen; Veli-Matti Kosma; Seppo Heinonen; Kari Alitalo; Seppo Yla-Herttuala
Journal:  Mol Ther       Date:  2008-12-02       Impact factor: 11.454

9.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.

Authors:  A Kaipainen; J Korhonen; T Mustonen; V W van Hinsbergh; G H Fang; D Dumont; M Breitman; K Alitalo
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

10.  Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib.

Authors:  Daniel J Crona; Andrew D Skol; Veli-Matti Leppänen; Dylan M Glubb; Amy S Etheridge; Eleanor Hilliard; Carol E Peña; Yuri K Peterson; Nancy Klauber-DeMore; Kari K Alitalo; Federico Innocenti
Journal:  Cancer Res       Date:  2018-11-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.